CD33-like protein

Details CD33-like protein CD33-like protein

2008-05-20

2008-05-20

Haddad, Maher M. (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C435S007100, C514S002600, C530S350000

Reexamination Certificate

active

07374764

ABSTRACT:
The present invention concerns a novel CD33-like protein. In particular, isolated nucleic acid molecules are provided encoding the CD33-like protein. Recombinant CD33-like polypeptides are also provided as are recombinant vectors and host cells. The invention further provides methods useful during tumor or inflammatory disease diagnosis or prognosis and therapeutic treatments targeting cells expressing CD33-like polypeptides.

REFERENCES:
patent: 6225446 (2001-05-01), Altmann et al.
patent: WO 97/20933 (1997-06-01), None
patent: WO 98/53840 (1998-12-01), None
patent: WO 99/06549 (1999-02-01), None
patent: WO 00/53757- (2000-09-01), None
patent: WO 00/53758- (2000-09-01), None
patent: WO 00/73452- (2000-12-01), None
Avril, et al., “Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation”,The Journal of Biological Chemistry, vol. 280, pp. 19843-19851, 2005.
Connolly, et al., “Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions”,British Journal of Haematology, vol. 119, pp. 221-238, 2002.
Erickson-Miller, et al., “Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes”,Experimental Haematology, vol. 31, pp. 382-388, 2003.
Lock, et al., “Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells”,Immunobiology, vol. 209, pp. 199-207, 2004.
Nguyen, et al., “Loss of Siglec expression on T lymphocytes during human evolution”,PNAS, vol. 103, pp. 7765-7770, 2006.
Rapoport, et al., “Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides”,Biochemistry(Moscow), vol. 71, pp. 496-504, 2006.
Virgo, et al., “Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias”,British Journal of Haematology, vol. 123, pp. 420-430, 2003.
Andrews, R.G. et al., “Myeloid-Associated Differentiation Antigens on Stem Cells and Their Progeny Identified by Monoclonal Antibodies,”Blood, 62(1):124-132 (1983).
Applebaum, F.R. et al., “The Use of Radiolabeled Anti-CD33 Antibody to Augment Marrow Irradiation Prior to Marrow Transplantation for Acute Myelogenous Leukemia,”Transplantation, 54(5):829-833 (1992).
Bernstein I.D. et al., “Treatment of Acute Myeloid Leukemia Cells In Vitro with a Monoclonal Antibody Recognizing a Myeloid Differentiation Antigen Allows Normal Progenitor Cells to be Expressed,”J. Clin. Invest., 79:1153-1159 (1987).
Caron, P.C. et al., “Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies,”Cancer Res., 52(24):6761-6767 (1992).
Caron, P.C. et al., “Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the Therapy of Acute Myelogenous Leukemia,”Suppl. to Cancer, 73(3):1049-1056 (1994).
Caron, P.C. et al., “A Phase 1B Trial of Humanized Monoclonal Antibody M195 (Anti-CD33) in Myeloid Leukemia: Specific Targeting Without Immunogenicity,”Blood, 83(7):1760-1768 (1994).
Freeman, S.D. et al., “Characterization of CD33 as a New Member of the Sialoadhesin Family of Cellular Interaction Molecules,”Blood, 85(8):2005-2012 (1995).
Griffin, J.D. et al., “A Monoclonal Antibody Reactive with Normal and Leukemic Human Myeloid Progenitor Cells,”Leukemia Res., 8(4):521-534 (1984).
Jurcic, J.G. et al., “Radiolabeled Anti-CD33 Monoclonal Antibody M195 for Myeloid Leukemias,”Cancer Res. (Suppl.), 55(23):5908s-5910s (1995).
Matutes, E. et al., “Characterization of Myeloid Leukemias with Monoclonal Antibodies 3C5 and MY9,”Hematological Onco., 3(3):179-186 (1985).
Pierelli, L. et al., “Further Investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ haematopoietic progenitor cells,”Brit. J. Haematology, 84:24-30 (1993).
Robertson, M.J. et al., “Human Bone Marrow Depleted of CD33-Positive Cells Mediated Delayed but Durable Reconstitution of Hematopoiesis: Clinical Trial of MY9 Monoclonal Leukemia,”Blood, 79(9):2229-2236 (1992).
Silla, L.M.R. et al., “Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc?RIII) expressed by human natural killer (NK) cells,”Brit. J. of Haematology, 89:712-718 (1995).
Simmons, D. and Seed, B., “Isolation of a cDNA Encoding CD33, a Differentiation Antigen of Myeloid Progenitor Cells,”J. Immuno., 141(8):2797-2800 (1988).
Stiff, P.J. et al., “Anti-CD33 Monoclonal Antibody and Etoposide/Cytosine Arabinoside Combinations for the Ex Vivo Purification of Bone Marrow in Acute Nonlymphocytic Leukemia,”Blood, 77(2):355-362 (1991).
Genbank Database, Accession No. M23197, Simmons, D. and Seed, B. (1994).
Genbank Database, Accession No. H71235, Hillier et al. (1995).
Genbank Report, Accession No. 2411475, Patel, N. et al. (Nov. 1996).
Genbank Report, Accession No. U71383, Patel, N. et al. (Sep. 1997).
NCBI Entrez Nucleotide Query, GenBank Accession No. AA186082, from Marra, M. et al. (Feb. 1997), with Revision History.
NCBI Entrez Nucleotide Query, GenBank Accession No. AA672534, from Marra, M. et al. (Nov. 1997), with Revision History.
NCBI Entrez Nucleotide Query, GenBank Accession No. AA676802, from Hillier, L. et al. (Dec. 1997), with Revision History.
NCBI Entrez Nucleotide Query, GenBank Accession No. T29458, from Adams, M.D. et al. (1995), with Revision History.
NCBI Entrez Nucleotide Query, GenBank Accession No. R96592, from Hillier, L. et al. (1995), with Revision History.
NCBI Entrez Nucleotide Query, GenBank Accession No. AA162826, from Marra, M. et al. (Feb. 1997), with Revision History.
Cornish, A.L. et al.,Blood, 92(6): 2123-2132 (The American Society of Hematology) (Sep. 1998).
Skolnick et al., “From genes to protein sructure and function: novel applications of computational approaches in the genomic era,”Tibtech, 18:34-39 (Jan. 2000).
Simmons et al., “Isolation of a cDNA Encoding CD33, A Differentiation Antigen of Myeloid Progenitor Cells,”J. Immunol., 141(8):2797-2800 (Oct. 1988).
Patel et al., “OB-BP1/Siglec-6—A Leptin- and Sialic Acid-Binding Protein of the Immunoglobulin Superfamily,”J. Biol. Chem., 274(32):22729-22738 (1999).

Affiliated with

Also associated with

Rating

CD33-like protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD33-like protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD33-like protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811262